Naproxen Label Shows Limitations Of Class Effect Thinking – Harvard’s Avorn
This article was originally published in The Tan Sheet
Executive Summary
The inclusion of naproxen in NSAID cardiovascular warning label requirements is an overextension of the use of "class effect" labeling, pharmacoepidemiologist Jerry Avorn, Harvard University, said
You may also be interested in...
Election 2008: Both Candidates Are Likely To Change FDA’s Direction
Whether Illinois Democrat Sen. Barack Obama or Arizona Republican Sen. John McCain wins the presidential election, signs point to a more activist FDA in 2009
Election 2008: Both Candidates Are Likely To Change FDA’s Direction
Whether Illinois Democrat Sen. Barack Obama or Arizona Republican Sen. John McCain wins the presidential election, signs point to a more activist FDA in 2009
Election 2008: Both Candidates Are Likely To Change FDA’s Direction
Whether Illinois Democrat Sen. Barack Obama or Arizona Republican Sen. John McCain wins the presidential election, signs point to a more activist FDA in 2009